Changes to the Code
S. 927 · Protecting Pharmacies in Medicaid Act · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
42 U.S.C. § 1396b Payment to States
3 changes the bill asks for here, 3 carried out
- Carried out:
by striking
and (III)
and inserting(III)
; - Carried out:
by inserting before the period at the end the following:
, and (IV) if the contract includes provisions making the entity responsible for coverage of covered outpatient drugs, the entity shall comply with the requirements of section 1927(e)(6)
; and - Carried out:
by adding at the end the following new paragraph:
(10) No payment shall be made under this title to a State with respect to expenditures incurred by the State for payment for services provided by an other specified entity (as defined in paragraph (9)(D)(iii)) unless such services are provided in accordance with a contract …
§ 1396b(m)(2)(A)–(B)
Start of § 1396b to (m)(2)(A)(xi) unchanged ·
(xii) such contract, and the entity complies with the applicable requirements of section 1396u–2 of this title; and
(xiii) such contract provides that (I) covered outpatient drugs dispensed to individuals eligible for medical assistance who are enrolled with the entity shall be subject to the same rebate required by the agreement entered into under section 1396r–8 of this title as the State is subject to and that the State shall collect such rebates from manufacturers, (II) capitation rates paid to the entity shall be based on actual cost experience related to rebates and subject to the Federal regulations requiring actuarially sound rates, [struck: and ](III) the entity shall report to the State, on such timely and periodic basis as specified by the Secretary in order to include in the information submitted by the State to a manufacturer and the Secretary under section 1396r–8(b)(2)(A) of this title, information on the total number of units of each dosage form and strength and package size by National Drug Code of each covered outpatient drug dispensed to individuals eligible for medical assistance who are enrolled with the entity and for which the entity is responsible for coverage of such drug under this subsection (other than covered outpatient drugs that under subsection (j)(1) of section 1396r–8 of this title are not subject to the requirements of that section) and such other data as the Secretary determines necessary to carry out this subsection[inserted: , and (IV) if the contract includes provisions making the entity responsible for coverage of covered outpatient drugs, the entity shall comply with the requirements of section 1927(e)(6)].
(B) Subparagraph (A)8 except with respect to clause (ix) of subparagraph (A), does not apply with respect to payments under this subchapter to a State with respect to expenditures incurred by it for payment for services provided by an entity which—
(i)
§ 1396b(m)–(o)
(m)(2)(B)(i)(I)–(9)(D)(iii) unchanged ·
(I) a prepaid inpatient health plan, as defined in section 438.2 of title 42, Code of Federal Regulations (or any successor regulation); and
(II) a prepaid ambulatory health plan, as defined in such section (or any successor regulation).
(10) [inserted: No payment shall be made under this title to a State with respect to expenditures incurred by the State for payment for services provided by an other specified entity (as defined in paragraph (9)(D)(iii)) unless such services are provided in accordance with a contract between the State and such entity which satisfies the requirements of paragraph (2)(A)(xiii).]
(n) Repealed. Pub. L. 100–93, § 8(h)(1), Aug. 18, 1987, 101 Stat. 694
(o) Restrictions on authorized payments to States Notwithstanding the preceding provisions of this section, no payment shall be made to a State under the preceding provisions of this section for expenditures for medical assistance provided for an individual under its State plan approved under this subchapter to the extent that a private insurer (as defined by the Secretary by regulation and including a group health plan (as defined in section 1167(1) of title 29), a service benefit plan, and a health maintenance organization) would have been obligated to provide such assistance but for a provision of its insurance contract which has the effect of limiting or excluding such obligation because the individual is eligible for or is provided medical assistance under the plan.
Rest of § 1396b unchanged ·
42 U.S.C. § 1396r–8 Payment for covered outpatient drugs
15 changes the bill asks for here, 11 carried out
- Carried out:
by redesignating clause (ii) as clause (iii); and
- Not carried out:
by striking and after the semicolon at the end of clause (i) and all that precedes it through (1) and inserting the following:
(1) Determining pharmacy actual acquisition costs.— The Secretary shall conduct a survey of retail community pharmacy drug prices and applicable non-retail pharmacy drug prices to determine national average drug acquisition cost benchmarks (as such term is defined by the …
We can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: striking QTEXT after the semicolon at the end of clause (X) and all that precedes it through QTEXT and inserting the following: QCONTENT; - Carried out:
in subparagraph (B) of paragraph (1), by striking
subparagraph (A)(ii)
and insertingsubparagraph (A)(iii)
; - Carried out:
in subparagraph (D) of paragraph (1), by striking clauses (ii) and (iii) and inserting the following:
(ii) The vendor must update the Secretary no less often than monthly on the survey prices for covered outpatient drugs. (iii) The vendor must differentiate, in collecting and reporting survey data, for all cost information collected, whether a pharmacy is a retail community …
- Not carried out:
by adding at the end of paragraph (1) the following:
(F) Survey reporting.— In order to meet the requirement of section 1902(a)(54), a State shall require that any retail community pharmacy or applicable non-retail pharmacy in the State that receives any payment, reimbursement, administrative fee, discount, rebate, or other price …
We can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: adding at the end of paragraph (X) the following: QCONTENT; - Not carried out:
in subparagraph (A), by inserting
, including payment rates and methodologies for determining ingredient cost reimbursement under managed care entities or other specified entities (as such terms are defined in section 1903(m)(9)(D)),
afterunder this title
; and“under this title” isn't in § 1396r–8(f)(2)(A) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“under this title” not found in /us/usc/t42/s1396r–8/f/2/A - Carried out:
in subparagraph (B), by inserting
and the basis for such dispensing fees
before the semicolon;
- Carried out:
by redesignating paragraph (4) as paragraph (5);
- Carried out:
by inserting after paragraph (3) the following new paragraph:
(4) Oversight.— (A) In general.— The Inspector General of the Department of Health and Human Services shall conduct periodic studies of the survey data reported under this subsection, as appropriate, including with respect to substantial variations in acquisition costs or other …
- Carried out:
by inserting
, and $9,000,000 for fiscal year 2026 and each fiscal year thereafter,
after2010
; and - Carried out:
by inserting
Funds appropriated under this paragraph for fiscal year 2026 and any subsequent fiscal year shall remain available until expended.
after the period.
- Not carried out:
in the matter preceding paragraph (1), by striking
In the section
and insertingIn this section
; and“In the section” isn't in § 1396r–8(k) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“In the section” not found in /us/usc/t42/s1396r–8/k - Carried out:
by adding at the end the following new paragraphs:
(12) Applicable non-retail pharmacy.— The term “applicable non-retail pharmacy” means a pharmacy that is licensed as a pharmacy by the State and that is not a retail community pharmacy, including a pharmacy that dispenses prescription medications to patients primarily through …
- Carried out:
in subsection (e), by adding at the end the following new paragraph:
(6) Transparent prescription drug pass-through pricing required.— (A) In general.— A contract between the State and a pharmacy benefit manager (referred to in this paragraph as a “PBM”), or a contract between the State and a managed care entity or other specified entity (as such …
- Carried out:
in subsection (k), as amended by section 2(b), by adding at the end the following new paragraph:
(14) Pharmacy benefit manager.— The term “pharmacy benefit manager” means any person or entity that, either directly or through an intermediary, acts as a price negotiator or group purchaser on behalf of a State, managed care entity (as defined in section 1903(m)(9)(D)), or …
§ 1396r–8(e)–(f)
Start of § 1396r–8 to (e)(3) unchanged ·
[(4) ]6 Establishment of upper payment limits Subject to paragraph (5), the Secretary shall establish a Federal upper reimbursement limit for each multiple source drug for which the FDA has rated three or more products therapeutically and pharmaceutically equivalent, regardless of whether all such additional formulations are rated as such and shall use only such formulations when determining any such upper limit.
(5) Use of amp in upper payment limits The Secretary shall calculate the Federal upper reimbursement limit established under paragraph (4) as no less than 175 percent of the weighted average (determined on the basis of utilization) of the most recently reported monthly average manufacturer prices for pharmaceutically and therapeutically equivalent multiple source drug products that are available for purchase by retail community pharmacies on a nationwide basis. The Secretary shall implement a smoothing process for average manufacturer prices. Such process shall be similar to the smoothing process used in determining the average sales price of a drug or biological under section 1395w–3a of this title.
(6) [inserted: Transparent prescription drug pass-through pricing required.—]
(A) [inserted: In general.—] [inserted: A contract between the State and a pharmacy benefit manager (referred to in this paragraph as a “PBM”), or a contract between the State and a managed care entity or other specified entity (as such terms are defined in section 1903(m)(9)(D) and collectively referred to in this paragraph as the “entity”) that includes provisions making the entity responsible for coverage of covered outpatient drugs dispensed to individuals enrolled with the entity, shall require that payment for such drugs and related administrative services (as applicable), including payments made by a PBM on behalf of the State or entity, is based on a transparent prescription drug pass-through pricing model under which—]
(i) [inserted: any payment made by the entity or the PBM (as applicable) for such a drug—]
(I) [inserted: is limited to—]
(aa) [inserted: ingredient cost; and]
(bb) [inserted: a professional dispensing fee that is not less than the professional dispensing fee that the State would pay if the State were making the payment directly in accordance with the State plan;]
(II) [inserted: is passed through in its entirety (except as reduced under Federal or State laws and regulations in response to instances of waste, fraud, or abuse) by the entity or PBM to the pharmacy or provider that dispenses the drug; and]
(III) [inserted: is made in a manner that is consistent with sections 447.502, 447.512, 447.514, and 447.518 of title 42, Code of Federal Regulations (or any successor regulation) as if such requirements applied directly to the entity or the PBM, except that any payment by the entity or the PBM for the ingredient cost of such drug purchased by a covered entity (as defined in subsection (a)(5)(B)) may exceed the actual acquisition cost (as defined in 447.502 of title 42, Code of Federal Regulations, or any successor regulation) for such drug if—]
(aa) [inserted: such drug was subject to an agreement under section 340B of the Public Health Service Act;]
(bb) [inserted: such payment for the ingredient cost of such drug does not exceed the maximum payment that would have been made by the entity or the PBM for the ingredient cost of such drug if such drug had not been purchased by such covered entity; and]
(cc) [inserted: such covered entity reports to the Secretary (in a form and manner specified by the Secretary), on an annual basis and with respect to payments for the ingredient costs of such drugs so purchased by such covered entity that are in excess of the actual acquisition costs for such drugs, the aggregate amount of such excess;]
(ii) [inserted: payment to the entity or the PBM (as applicable) for administrative services performed by the entity or PBM is limited to an administrative fee that reflects the fair market value (as defined by the Secretary) of such services;]
(iii) [inserted: the entity or the PBM (as applicable) makes available to the State, and the Secretary upon request in a form and manner specified by the Secretary, all costs and payments related to covered outpatient drugs and accompanying administrative services (as described in clause (ii)) incurred, received, or made by the entity or the PBM, broken down (as specified by the Secretary), to the extent such costs and payments are attributable to an individual covered outpatient drug, by each such drug, including any ingredient costs, professional dispensing fees, administrative fees (as described in clause (ii)), post-sale and post-invoice fees, discounts, or related adjustments such as direct and indirect remuneration fees, and any and all other remuneration, as defined by the Secretary; and]
(iv) [inserted: any form of spread pricing whereby any amount charged or claimed by the entity or the PBM (as applicable) that exceeds the amount paid to the pharmacies or providers on behalf of the State or entity, including any post-sale or post-invoice fees, discounts, or related adjustments such as direct and indirect remuneration fees or assessments, as defined by the Secretary, (after allowing for an administrative fee as described in clause (ii)) is not allowable for purposes of claiming Federal matching payments under this title.]
(B) [inserted: Publication of information.—] [inserted: The Secretary shall publish, not less frequently than on an annual basis and in a manner that does not disclose the identity of a particular covered entity or organization, information received by the Secretary pursuant to subparagraph (A)(iii)(III) that is broken out by State and by each of the following categories of covered entity within each such State:]
(i) [inserted: Covered entities described in subparagraph (A) of section 340B(a)(4) of the Public Health Service Act.]
(ii) [inserted: Covered entities described in subparagraphs (B) through (K) of such section.]
(iii) [inserted: Covered entities described in subparagraph (L) of such section.]
(iv) [inserted: Covered entities described in subparagraph (M) of such section.]
(v) [inserted: Covered entities described in subparagraph (N) of such section.]
(vi) [inserted: Covered entities described in subparagraph (O) of such section.]
(f) Survey of retail prices; State payment and utilization rates; and performance rankings
(1) Survey of retail prices
(A) Use of vendor The Secretary may contract services for—
(i) with respect to a retail community pharmacy, the determination on a monthly basis of retail survey prices for covered outpatient drugs that represent a nationwide average of consumer purchase prices for such drugs, net of all discounts and rebates (to the extent any information with respect to such discounts and rebates is available); and
[struck: (ii)] [inserted: (iii)] the notification of the Secretary when a drug product that is therapeutically and pharmaceutically equivalent and bioequivalent becomes generally available.
(B) Secretary response to notification of availability of multiple source products If contractor notifies the Secretary under subparagraph (A)([struck: ii][inserted: iii]) that a drug product described in such subparagraph has become generally available, the Secretary shall make a determination, within 7 days after receiving such notification, as to whether the product is now described in subsection (e)(4).4
(C) Use of competitive bidding In contracting for such services, the Secretary shall competitively bid for an outside vendor that has a demonstrated history in—
(i) surveying and determining, on a representative nationwide basis, retail prices for ingredient costs of prescription drugs;
§ 1396r–8(f)–(g)
(f)(1)(C)(ii)–(D) unchanged ·
(i) The vendor must monitor the marketplace and report to the Secretary each time there is a new covered outpatient drug generally available.
(ii) The vendor must update the Secretary no less often than monthly on the [struck: retail ]survey prices for covered outpatient drugs.
(iii) The [struck: contract][inserted: vendor] [struck: shall][inserted: must] [struck: be][inserted: differentiate,] [struck: effective][inserted: in] [inserted: collecting and reporting survey data, ]for [inserted: all cost information collected, whether ]a [struck: term][inserted: pharmacy] [inserted: is a retail community pharmacy or an applicable non-retail pharmacy, including whether such pharmacy is an affiliate (as defined in subsection (k)(14)), and, in the case ]of [inserted: an applicable non-retail pharmacy, which type of applicable non-retail pharmacy it is using the relevant pharmacy type indicators included in the guidance required by subsection (d)(]2[inserted: )] [struck: years][inserted: of section 2 of the Protecting Pharmacies in Medicaid Act].
(E) Availability of information to States Information on retail survey prices obtained under this paragraph, including applicable information on single source drugs, shall be provided to States on at least a monthly basis. The Secretary shall devise and implement a means for providing access to each State agency designated under section 1396a(a)(5) of this title with responsibility for the administration or supervision of the administration of the State plan under this subchapter of the retail survey price determined under this paragraph.
(2) Annual State report Each State shall annually report to the Secretary information on—
(A) the payment rates under the State plan under this subchapter for covered outpatient drugs;
(B) the dispensing fees paid under such plan for such drugs[inserted: and the basis for such dispensing fees]; and
(C) utilization rates for noninnovator multiple source drugs under such plan.
(3) Annual State performance rankings
(A) Comparative analysis The Secretary annually shall compare, for the 50 most widely prescribed drugs identified by the Secretary, the national retail sales price data (collected under paragraph (1)) for such drugs with data on prices under this subchapter for each such drug for each State.
(B) Availability of information The Secretary shall submit to Congress and the States full information regarding the annual rankings made under subparagraph (A).
(4) [inserted: Oversight.—]
(A) [inserted: In general.—] [inserted: The Inspector General of the Department of Health and Human Services shall conduct periodic studies of the survey data reported under this subsection, as appropriate, including with respect to substantial variations in acquisition costs or other applicable costs, as well as with respect to how internal transfer prices and related party transactions may influence the costs reported by pharmacies that are affiliates (as defined in subsection (k)(14)) or are owned by, controlled by, or related under a common ownership structure with a wholesaler, distributor, or other entity that acquires covered outpatient drugs relative to costs reported by pharmacies not affiliated with such entities. The Inspector General shall provide periodic updates to Congress on the results of such studies, as appropriate, in a manner that does not disclose trade secrets or other proprietary information.]
(B) [inserted: Appropriation.—] [inserted: There is appropriated to the Inspector General of the Department of Health and Human Services, out of any money in the Treasury not otherwise appropriated, $5,000,000 for fiscal year 2026, to remain available until expended, to carry out this paragraph.]
[struck: (4)] [inserted: (5)] Appropriation Out of any funds in the Treasury not otherwise appropriated, there is appropriated to the Secretary of Health and Human Services $5,000,000 for each of fiscal years 2006 through 2010[inserted: ,] [inserted: and $9,000,000 for fiscal year 2026 and each fiscal year thereafter, ]to carry out this subsection.[inserted: Funds appropriated under this paragraph for fiscal year 2026 and any subsequent fiscal year shall remain available until expended.]
(g) Drug use review
(1) In general
(A) In order to meet the requirement of section 1396a(a)(54) of this title, a State shall provide for a drug use review program described in paragraph (2) for covered outpatient drugs in order to assure that prescriptions (i) are appropriate, (ii) are medically necessary, and (iii) are not likely to result in adverse medical results. The program shall be designed to educate physicians and pharmacists to identify and reduce the frequency of patterns of fraud, abuse, gross overuse, excessive utilization, inappropriate or medically unnecessary care, or prescribing or billing practices that indicate abuse or excessive utilization, among physicians, pharmacists, and patients, or associated with specific drugs or groups of drugs, as well as potential and actual severe adverse reactions to drugs including education on therapeutic appropriateness, overutilization and underutilization, appropriate use of generic products, therapeutic duplication, drug-disease contraindications, drug-drug interactions, incorrect drug dosage or duration of drug treatment, drug-allergy interactions, and clinical abuse/misuse.
§ 1396r–8(k)Definitions(10)–(14)
(g)(1)(B)–(k)(9) unchanged ·
(10) Retail community pharmacy The term “retail community pharmacy” means an independent pharmacy, a chain pharmacy, a supermarket pharmacy, or a mass merchandiser pharmacy that is licensed as a pharmacy by the State and that dispenses medications to the general public at retail prices. Such term does not include a pharmacy that dispenses prescription medications to patients primarily through the mail, nursing home pharmacies, long-term care facility pharmacies, hospital pharmacies, clinics, charitable or not-for-profit pharmacies, government pharmacies, or pharmacy benefit managers.
(11) Wholesaler The term “wholesaler” means a drug wholesaler that is engaged in wholesale distribution of prescription drugs to retail community pharmacies, including (but not limited to) repackers, distributors, own-label distributors, private-label distributors, jobbers, brokers, warehouses (including distributor’s warehouses, chain drug warehouses, and wholesale drug warehouses) independent wholesale drug traders, and retail community pharmacies that conduct wholesale distributions.
(12) [inserted: Applicable non-retail pharmacy.—] [inserted: The term “applicable non-retail pharmacy” means a pharmacy that is licensed as a pharmacy by the State and that is not a retail community pharmacy, including a pharmacy that dispenses prescription medications to patients primarily through mail and specialty pharmacies. Such term does not include nursing home pharmacies, long-term care facility pharmacies, hospital pharmacies, clinics, charitable or not-for-profit pharmacies, government pharmacies, or low dispensing pharmacies (as defined by the Secretary).]
(13) [inserted: Affiliate.—] [inserted: The term “affiliate” means any entity that is owned by, controlled by, or related under a common ownership structure with a pharmacy benefit manager or a managed care entity or other specified entity (as such terms are defined in section 1903(m)(9)(D)).]
(14) [inserted: Pharmacy benefit manager.—] [inserted: The term “pharmacy benefit manager” means any person or entity that, either directly or through an intermediary, acts as a price negotiator or group purchaser on behalf of a State, managed care entity (as defined in section 1903(m)(9)(D)), or other specified entity (as so defined), or manages the prescription drug benefits provided by a State, managed care entity, or other specified entity, including the processing and payment of claims for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the managing of appeals or grievances related to the prescription drug benefits, contracting with pharmacies, controlling the cost of covered outpatient drugs, or the provision of services related thereto. Such term includes any person or entity that acts as a price negotiator (with regard to payment amounts to pharmacies and providers for a covered outpatient drug or the net cost of the drug) or group purchaser on behalf of a State, managed care entity, or other specified entity or that carries out 1 or more of the other activities described in the preceding sentence, irrespective of whether such person or entity calls itself a pharmacy benefit manager.]